A61K 39/001129
Molecules with a "cd" designation not provided for elsewhere
Official title: {Molecules with a "CD" designation not provided for elsewhere}
A61K39/001129 (Molecules with a "cd" designation not provided for elsewhere) appears on 119 US grants and 244 published applications in this corpus.
Search patents in A61K- Granted patents
- 119
- Published applications
- 244
- Assignees
- 159
- Inventors
- 486
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 3 |
| 2004 | 0 | 3 |
| 2005 | 0 | 4 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 5 |
| 2011 | 1 | 10 |
| 2012 | 4 | 2 |
| 2013 | 1 | 4 |
| 2014 | 5 | 6 |
| 2015 | 2 | 12 |
| 2016 | 8 | 14 |
| 2017 | 6 | 13 |
| 2018 | 6 | 14 |
| 2019 | 3 | 12 |
| 2020 | 7 | 24 |
| 2021 | 8 | 26 |
| 2022 | 17 | 22 |
| 2023 | 15 | 20 |
| 2024 | 23 | 21 |
| 2025 | 8 | 16 |
| 2026 | 3 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Trispecific binding molecules against BCMA and uses thereof12 May 2026US 12,624,118 B2Novartis AG
- Hepatitis B virus-specific T cell responses14 Apr 2026US 12,599,658 B2Oregon Health & Science University
- Antibodies binding CD40 and uses thereof23 Dec 2025US 12,503,517 B2Biosion Inc.
- Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen16 Dec 2025US 12,496,339 B2Abacus Bioscience, Inc.
- Switchable mrna expression platform6 Aug 2026US 2026/0224679 A1
- Method for treating local and distant tumors28 May 2026US 2026/0144760 A1IntraAb, Inc.
- Mrna composition for treating cancer, preparation containing the same and use thereof28 May 2026US 2026/0144810 A1Industrial Technology Research Institute
- Methods for modulating regulatory t cells28 May 2026US 2026/0146102 A1Universite de Lausanne
- Bispecific antibodies against ceacam5 and cd323 Apr 2026US 2026/0109779 A1Lamkap Bio Alpha AG
Most cited
By later US patents
- Application of mRNA for use as a therapeutic agent for tumorous diseases194US 8,217,016 B2CureVac AG · 2012
- Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof79US 9,572,874 B2CureVac AG · 2017
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Application of mRNA for use as a therapeutic against tumour diseases65US 9,155,788 B2CureVac AG · 2015
- Combination of the application of antibodies for immunostimulation together with glucocorticoids58US 8,709,421 B2Trion Pharma GmbH · 2014